Orexigen Therapeutics to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO, Feb. 7, 2013 SAN DIEGO, Feb. 7, 2013 /PRNewswire/ --Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are as follows: The 15th Annual BIO CEO & Investor Conference Date: Tuesday, February 12, 2013 Time: 2:00 p.m. Eastern Time Location: The Waldorf Astoria, New York 2013 Leerink Swann Global Healthcare Conference Date: Wednesday, February 13, 2013 Time: 11:30 a.m. Eastern Time Location: The Waldorf Astoria, New York The BIO CEO & Investor Conference presentation will be webcast live. To access the webcast, please visit the Investor Relations section of the company's Web site at www.orexigen.com. A replay will be available for 14 days after the event. About Orexigen® Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com. Orexigen Contact: McDavid Stilwell VP, Corporate Communications and Business Development (858) 875-8629 Media Contact: Denise Powell BrewLife (510) 703-9491 SOURCE Orexigen Therapeutics, Inc. Website: http://www.orexigen.com
Orexigen Therapeutics to Present at Upcoming Investor Conferences
Press spacebar to pause and continue. Press esc to stop.